Baird P A
University of British Columbia, Vancouver.
CMAJ. 1996 Aug 1;155(3):299-301.
Public funding for medical and health-related research in Canada is declining. At the same time, the pharmaceutical industry is directing increasing amounts of money to publicly funded agencies such as universities and the Medical Research Council of Canada. However, the kinds of research most valuable to commercial firms may not be those most valuable to the Canadian public. There is a danger that research priorities and activities in public institutions may become skewed as a result of increased drug-industry funding. Mechanisms need to be found to ensure an appropriate balance between the research that is most valuable to the public interest and to the long-term advancement of knowledge, and the research that is likely to lead to marketable products. One such mechanism is the direction of a proportion of the money from drug companies to a "no-strings-attached" fund specifically to support types of research that are in the public interest but not likely to lead to marketable products.
加拿大用于医疗及健康相关研究的公共资金正在减少。与此同时,制药行业正将越来越多的资金投入到诸如大学和加拿大医学研究理事会等公共资助机构。然而,对商业公司最具价值的研究类型可能并非对加拿大公众最具价值的研究类型。由于制药行业资金投入增加,公共机构的研究重点和活动存在被扭曲的风险。需要找到一些机制,以确保在对公众利益和知识的长期进步最有价值的研究,与可能带来适销产品的研究之间实现适当平衡。一种这样的机制是将制药公司的一部分资金导向一个“无附加条件”的基金,专门用于支持符合公众利益但不太可能带来适销产品的研究类型。